Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04052425 · ClinicalTrials.gov registry record · Phase 3
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
A Phase 3 study of Non-segmental Vitiligo, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
- 20
- Study locations
NCT04052425 is a Phase 3 study of Non-segmental Vitiligo that has completed, run by Incyte Corporation. The registered enrollment target is 330 participants, above the 160-participant average among 5 other Non-segmental Vitiligo trials with a reported enrollment target (106% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT04052425, a Phase 3 study of Non-segmental Vitiligo, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG Ruxolitinib cream
Study Locations (20)
Florida
- Harmony Medical Research Institute - Hialeah
- San Marcus Research Clinic Inc. - Miami Lakes
- ForCare Medical Center - Tampa
- Forcare Clinical Research Fcr Forward Clinical Trials, Inc - Tampa
- Metabolic Research Institute Inc - West Palm Beach
California
- First Oc Dermatology - Fountain Valley
- Marvel Clinical Research Llc - Huntington Beach
- Rady Children'S Hospital - San Diego - San Diego
- University of California San Francisco Sub Location - San Francisco
New York
- Suny Downstate Medical Center - Brooklyn
- Forest Hills Dermatology Group - Forest Hills
- The Dermatology Specialists Greenwich - New York
Michigan
- Great Lakes Research Group Inc - Bay City
- Dermatology Specialists of Brighton - Brighton
Alabama
- Cahaba Dermatology - Hoover
Arizona
- Cognitive Clinical Trials Scottsdale Btc Ppds - Scottsdale
Arkansas
- Burke Pharmaceutical Research - Hot Springs
Connecticut
- Clinical Research Center of Ct - Danbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2019-09-20 |
| Est. Completion | 2021-10-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04052425
The ClinicalTrials.gov registry entry for NCT04052425 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 160-participant average among 5 other Non-segmental Vitiligo trials with a reported enrollment target (106% higher). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-segmental Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT04052425 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT04052425 about?
NCT04052425 is a clinical study titled "Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)". The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).
What is the current status of trial NCT04052425?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2019-09-20. Estimated completion is 2021-10-21.
What conditions does trial NCT04052425 study?
This clinical trial studies the following conditions: Non-segmental Vitiligo.
What interventions are being tested in trial NCT04052425?
The interventions under investigation include: Vehicle (DRUG), Ruxolitinib cream (DRUG).
Who is sponsoring clinical trial NCT04052425?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04052425 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-segmental Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
RECRUITING · Phase 2
-
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
RECRUITING · Phase 2
-
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.